Further in vitro experiments confirmed that HER2 amplification activated downstream AKT and ERK signaling pathways and continued to activate them even when the EGFR signaling pathway was inhibited, leading to NSCLC cell resistance to EGFR TKIs (47). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.